Related Experiment Video
Updated: Jan 9, 2026
05:49
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
Published on: October 10, 2019
7.0K
Extending Current Guideline-recommended Prostate-specific Antigen Density Thresholds for Improving Benefit/Harm
Anne M A Prinsen1, Ivo M Wagensveld2, Daniel F Osses3
1Department of Urology, Sint Antonius Ziekenhuis, Nieuwegein, The Netherlands.
European Urology Oncology
|November 29, 2025
Summary
Optimizing prostate cancer (PCa) diagnosis, this study suggests using higher PSA density thresholds to safely reduce unnecessary biopsies and MRI scans in biopsy-naïve men. This approach enhances the benefit-to-harm ratio for risk-based PCa diagnostics.
Area of Science:
- Uro-oncology
- Diagnostic imaging
- Prostate cancer screening
Background:
- International guidelines advocate for risk-based magnetic resonance imaging (MRI)-directed pathways to minimize prostate cancer (PCa) overdiagnosis.
- Prostate-specific antigen (PSA) density is a key biomarker for stratifying patients for MRI or biopsy.
- Reducing unproductive diagnostic interventions is crucial in PCa management.
Purpose of the Study:
- To evaluate a risk-based MRI-directed pathway using PSA density thresholds for MRI and/or targeted biopsy in men with suspected PCa.
- To assess the safety and efficacy of these thresholds in reducing unnecessary procedures while detecting clinically significant PCa.
- To optimize the benefit-to-harm ratio in PCa diagnostics.
Main Methods:
- Post hoc analysis of the prospective multicentre MR-PROPER study (MRI arm).
- Investigated PSA density thresholding strategies in biopsy-naïve men with suspected PCa and PI-RADS score ≥3.
- Evaluated outcomes including grade group (GG) ≥2 cancer detection, avoided MRI scans, negative biopsies, and GG1 cancer detection.
Main Results:
- A post-MRI PSA density threshold of ≥0.20 ng/ml² for PI-RADS 3 lesions detected 98.7% of GG≥2 cancers, avoided 29% of negative biopsies, and reduced GG1 detection.
- A pre-MRI PSA density threshold of ≥0.10 ng/ml² avoided 38% of unproductive biopsies and 30% of MRI scans, with a 9.6% risk of missing GG≥2 cancers.
- The study included 996 men, with a 24% detection rate for GG≥2 PCa.
Conclusions:
- Applying a post-MRI PSA density threshold of ≥0.20 ng/ml² for PI-RADS 3 lesions in a community setting improves the benefit-to-harm ratio by reducing unnecessary biopsies without compromising oncological safety.
- A pre-MRI PSA density threshold of ≥0.10 ng/ml² for MRI indication offers a favorable benefit-to-harm ratio but requires careful consideration due to narrow safety margins.
- These findings support risk-adapted diagnostic strategies, particularly in settings aiming to minimize patient burden and healthcare costs.
